Ki67蛋白表达与神经胶质瘤患者临床分期及预后的相关性分析

Relationship of Ki67 expression with the clinical stage and prognosis of neuroglioma patients

目的分析Ki67及Bmi1蛋白表达与神经胶质瘤患者临床分期及预后的相关性,为临床神经胶质瘤的诊断及治疗提供参考。方法回顾性分析2012年1月至2016年1月期间诊治的114例神经胶质瘤患者临床资料,分析不同临床分期患者Ki67及Bmi1蛋白的表达水平,研究Ki67及Bmi1表达水平与患者预后的相关性。以同期健康体检者120例为对照组。结果神经胶质瘤组织中Ki67及Bmi1蛋白表达与TNM分期及肿瘤是否有远处转移具有一定的相关性(P<0.05),而与性别、年龄、肿瘤大小等无关(P>0.05);酶联免疫吸附测定和Western Blotting检测分析发现神经胶质瘤患者Ki67及Bmi1蛋白水平明显高于对照组(P<0.05),且随着临床分期的增加,上述蛋白的表达逐渐升高(P<0.05);随着Ki67及Bmi1蛋白表达的增强,神经胶质瘤患者预后逐年变差。结论 Ki67及Bmi1蛋白表达与神经胶质瘤患者临床分期及预后呈明显的负相关。

Objective To explore the relationship of Ki67 expression with the clinical stage and prognosis of neuroglioma patients.Methods 114 cases of glioma patient＇＇s data from Jan 2013 to Jan 2016 were enrolled in this part.The relationship of Ki67 expression with the clinical stage and prognosis were assayed.120 healthy subjects at the same period were taken as control.Results The results showed that the Ki67 and Bmi1 protein expression had a close relationship with clinical stage and metastasis.ELISA and Western Blotting results showed that the expression of Ki67 and Bmi1 were higher greatly in glioma patients than that of control group with statistical difference.At the same time, these proteins were increased with the severe of the clinical stages.The result also revealed that the higher expression of Ki67 and Bmi1, the worse prognosis of glioma patients.Conclusion Ki67 and Bmi1 have a close relationship with the clinical stage of glioma stage and negatively related with the prognosis.